Abivax stock plunges after cancer cases cloud bowel disease drug trial
Jefferies downgraded the French biotech to Hold and cut its price target nearly in half, warning the cancer overhang won't resolve quickly
Overview
Jefferies downgraded the French biotech to Hold and cut its price target nearly in half, warning the cancer overhang won't resolve quickly
Source
Originally published at qz.com.
Related Articles
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Data may be delayed up to 15 minutes. Past performance is not indicative of future results. Consult a licensed financial advisor before making investment decisions.
